Parkinson's Disease Global Market Report 2025

Description

Parkinson's disease is a degenerative neurological disorder that impacts movement due to the loss of dopamine-producing cells in the brain. It primarily results in tremors, muscle stiffness, slowed movements, and balance issues. Treatment typically includes medications such as levodopa to manage symptoms, often supplemented with physical therapy and, in some cases, surgical options such as deep brain stimulation.

The main classes of drugs used to treat Parkinson's disease consist of dopamine agonists, catechol-O-methyltransferase inhibitors, monoamine oxidase B inhibitors, anticholinergics, carbidopa-levodopa, and others. Dopamine agonists, for example, mimic dopamine's effects in the brain to help control symptoms. These drugs can be administered via various routes, including oral, injectable, intestinal infusion, subcutaneous, and other methods, depending on treatment requirements. Additionally, the distribution channels for Parkinson's disease medications include retail pharmacies, hospital pharmacies, and online pharmacies, ensuring broad accessibility. Most patient care for Parkinson's disease is managed in clinics and hospitals, where healthcare professionals can closely monitor and treat the condition.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The parkinson's disease market research report is one of a series of new reports from The Business Research Company that provides parkinson's disease market statistics, including parkinson's disease industry global market size, regional shares, competitors with a parkinson's disease market share, detailed parkinson's disease market segments, market trends and opportunities, and any further data you may need to thrive in the parkinson's disease industry. This parkinson's disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The parkinson's disease market size has grown strongly in recent years. It will grow from $3.34 billion in 2024 to $3.62 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increasing research and development, growth in government funding, growth in personalized treatment plans, growth in support networks for Parkinson's disease patients, and increasing use of advanced rehabilitation therapies.

The parkinson's disease market size is expected to see strong growth in the next few years. It will grow to $4.94 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to rising awareness about parkinson's disease symptoms, rising government initiatives, increasing healthcare spending, a rising number of Parkinson's disease clinical trials, and rising adoption of gene therapies. Major trends in the forecast period include technological advancements, government initiatives and funding, artificial intelligence in diagnosis, innovative solutions, and personalized medicine.

The forecast of 8.1% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of deep brain stimulation (DBS) devices and levodopa-carbidopa intestinal gel (LCIG) sourced from Sweden and Ireland, exacerbating out-of-pocket expenses and limiting neurological care access. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of neurodegenerative diseases is expected to drive the growth of the Parkinson's disease market. Neurodegenerative diseases are a group of disorders characterized by the progressive degeneration and loss of function of neurons in the brain and nervous system. Several factors contribute to the rising prevalence of these conditions, including an aging population, genetic predisposition, environmental influences, improved diagnosis, chronic health conditions, and lifestyle changes. Parkinson's disease plays a crucial role in advancing the understanding of neurodegenerative diseases by offering insights into their underlying mechanisms, identifying potential therapeutic targets, and developing innovative treatment approaches. For instance, in April 2022, the European Brain Council reported that over 600 neurological diseases and nearly 300 psychiatric conditions affect millions globally, with 65 million people suffering from epilepsy. In Europe alone, 10.5 million people have dementia, with projections indicating an increase to 18.7 million by 2050. As a result, the rising prevalence of neurodegenerative diseases is fueling the expansion of the Parkinson's disease market.

Leading companies in the Parkinson's disease market are focusing on innovative treatment solutions, such as levodopa-based therapy, to enhance motor function and provide continuous symptom management for patients with advanced Parkinson's disease. Levodopa-based therapy involves using levodopa, a medication that converts into dopamine in the brain, to alleviate symptoms and improve motor function. For example, in October 2024, AbbVie Inc., a U.S.-based biopharmaceutical company, received FDA approval for VYALEV, a combination therapy containing levodopa and carbidopa designed for treating Parkinson's disease. This formulation enhances the efficacy of levodopa by preventing its breakdown before reaching the brain, thereby increasing dopamine levels. The medication effectively manages motor symptoms such as tremors, rigidity, and bradykinesia, helping patients maintain daily activities and improving their quality of life. It is considered a key therapeutic solution for patients with Parkinson's disease experiencing motor fluctuations.

In August 2024, AbbVie Inc. expanded its neuroscience portfolio by acquiring Cerevel Therapeutics Holdings Inc., a US-based biotechnology company specializing in treatments for Parkinson's disease. This acquisition aims to strengthen AbbVie's position in addressing unmet medical needs in psychiatric and neurological disorders, reinforcing its commitment to developing innovative therapies for neurodegenerative diseases.

Major players in the parkinson's disease market are Roche Holding AG, AbbVie Inc., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, UCB S.A., Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Amneal Pharmaceuticals Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., Intracellular Therapies Inc., Voyager Therapeutics Inc., Sage Therapeutics Inc., Adamas Pharmaceuticals Inc., Sun Pharma Advanced Research Company Ltd., Neuraly Inc., Mitsubishi Tanabe Pharma Corporation, Athira Pharma Inc., VistaGen Therapeutics Inc.

North America was the largest region in the parkinson's disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in parkinson's disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the parkinson's disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The parkinson's disease market consists of revenues earned by entities providing services such as speech therapy, and physical therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The parkinson's disease market also includes sales of amantadine and adenosine A2A receptor antagonists. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Parkinson's Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on parkinson's disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for parkinson's disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The parkinson's disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: Dopamine Agonists; Catechol-O-Methyltransferase Inhibitors; Monoamine Oxidase B Inhibitors; Anticholinergics; Carbidopa-Levodopa; Other Drug Classes
2) By Route Of Administration: Oral; Injectable; Intestinal infusion; Subcutaneous; Other Route Of Administrations
3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Pharmacies
4) By Patient Care Setting: Clinics; Hospitals
Subsegments:
1) By Dopamine Agonists: Ergot Derivatives; Non-Ergot Derivatives
2) By Catechol-O-Methyltransferase (COMT) Inhibitors: Entacapone; Tolcapone; Opicapone
3) By Monoamine Oxidase B (MAO-B) Inhibitors: Selegiline; Rasagiline; Safinamide
4) By Anticholinergics: Trihexyphenidyl; Benztropine; Procyclidine
5) By Carbidopa-Levodopa: Immediate-Release Formulation; Extended-Release Formulation; Inhaled And Intestinal Gel Formulations
6) By Other Drug Classes: Amantadine And Derivatives; Adenosine A2A Receptor Antagonists; Glutamate Antagonists
Companies Mentioned: Roche Holding AG; AbbVie Inc.; Novo Nordisk A/S; Takeda Pharmaceutical Company Limited; UCB S.A.; Eisai Co. Ltd.; Kyowa Kirin Co. Ltd.; Amneal Pharmaceuticals Inc.; Neurocrine Biosciences Inc.; Supernus Pharmaceuticals Inc.; Sunovion Pharmaceuticals Inc.; Intracellular Therapies Inc.; Voyager Therapeutics Inc.; Sage Therapeutics Inc.; Adamas Pharmaceuticals Inc.; Sun Pharma Advanced Research Company Ltd.; Neuraly Inc.; Mitsubishi Tanabe Pharma Corporation; Athira Pharma Inc.; VistaGen Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r34113u

1. Executive Summary

2. Parkinson's Disease Market Characteristics

3. Parkinson's Disease Market Trends And Strategies

4. Parkinson's Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Parkinson's Disease Growth Analysis And Strategic Analysis Framework

5.1. Global Parkinson's Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Parkinson's Disease Market Growth Rate Analysis
5.4. Global Parkinson's Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Parkinson's Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Parkinson's Disease Total Addressable Market (TAM)

6. Parkinson's Disease Market Segmentation

6.1. Global Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Dopamine Agonists
Catechol-O-Methyltransferase Inhibitors
Monoamine Oxidase B Inhibitors
Anticholinergics
Carbidopa-Levodopa
Other Drug Classes
6.2. Global Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
Intestinal infusion
Subcutaneous
Other Route Of Administrations
6.3. Global Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
6.4. Global Parkinson's Disease Market, Segmentation By Patient Care Setting, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Clinics
Hospitals
6.5. Global Parkinson's Disease Market, Sub-Segmentation Of Dopamine Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ergot Derivatives
Non-Ergot Derivatives
6.6. Global Parkinson's Disease Market, Sub-Segmentation Of Catechol-O-Methyltransferase (COMT) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Entacapone
Tolcapone
Opicapone
6.7. Global Parkinson's Disease Market, Sub-Segmentation Of Monoamine Oxidase B (MAO-B) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Selegiline
Rasagiline
Safinamide
6.8. Global Parkinson's Disease Market, Sub-Segmentation Of Anticholinergics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Trihexyphenidyl
Benztropine
Procyclidine
6.9. Global Parkinson's Disease Market, Sub-Segmentation Of Carbidopa-Levodopa, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immediate-Release Formulation
Extended-Release Formulation
Inhaled And Intestinal Gel Formulations
6.10. Global Parkinson's Disease Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Amantadine And Derivatives
Adenosine A2A Receptor Antagonists
Glutamate Antagonists

7. Parkinson's Disease Market Regional And Country Analysis

7.1. Global Parkinson's Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Parkinson's Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Parkinson's Disease Market

8.1. Asia-Pacific Parkinson's Disease Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Parkinson's Disease Market

9.1. China Parkinson's Disease Market Overview
9.2. China Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Parkinson's Disease Market

10.1. India Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Parkinson's Disease Market

11.1. Japan Parkinson's Disease Market Overview
11.2. Japan Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Parkinson's Disease Market

12.1. Australia Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Parkinson's Disease Market

13.1. Indonesia Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Parkinson's Disease Market

14.1. South Korea Parkinson's Disease Market Overview
14.2. South Korea Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Parkinson's Disease Market

15.1. Western Europe Parkinson's Disease Market Overview
15.2. Western Europe Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Parkinson's Disease Market

16.1. UK Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Parkinson's Disease Market

17.1. Germany Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Parkinson's Disease Market

18.1. France Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Parkinson's Disease Market

19.1. Italy Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Parkinson's Disease Market

20.1. Spain Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Parkinson's Disease Market

21.1. Eastern Europe Parkinson's Disease Market Overview
21.2. Eastern Europe Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Parkinson's Disease Market

22.1. Russia Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Parkinson's Disease Market

23.1. North America Parkinson's Disease Market Overview
23.2. North America Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Parkinson's Disease Market

24.1. USA Parkinson's Disease Market Overview
24.2. USA Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Parkinson's Disease Market

25.1. Canada Parkinson's Disease Market Overview
25.2. Canada Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Parkinson's Disease Market

26.1. South America Parkinson's Disease Market Overview
26.2. South America Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Parkinson's Disease Market

27.1. Brazil Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Parkinson's Disease Market

28.1. Middle East Parkinson's Disease Market Overview
28.2. Middle East Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Parkinson's Disease Market

29.1. Africa Parkinson's Disease Market Overview
29.2. Africa Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Parkinson's Disease Market Competitive Landscape And Company Profiles

30.1. Parkinson's Disease Market Competitive Landscape
30.2. Parkinson's Disease Market Company Profiles
- 30.2.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. UCB S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Parkinson's Disease Market Other Major And Innovative Companies

31.1. Eisai Co. Ltd.
31.2. Kyowa Kirin Co. Ltd.
31.3. Amneal Pharmaceuticals Inc.
31.4. Neurocrine Biosciences Inc.
31.5. Supernus Pharmaceuticals Inc.
31.6. Sunovion Pharmaceuticals Inc.
31.7. Intracellular Therapies Inc.
31.8. Voyager Therapeutics Inc.
31.9. Sage Therapeutics Inc.
31.10. Adamas Pharmaceuticals Inc.
31.11. Sun Pharma Advanced Research Company Ltd.
31.12. Neuraly Inc.
31.13. Mitsubishi Tanabe Pharma Corporation
31.14. Athira Pharma Inc.
31.15. VistaGen Therapeutics Inc.

32. Global Parkinson's Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Parkinson's Disease Market

34. Recent Developments In The Parkinson's Disease Market

35. Parkinson's Disease Market High Potential Countries, Segments and Strategies

35.1 Parkinson's Disease Market In 2029 - Countries Offering Most New Opportunities
35.2 Parkinson's Disease Market In 2029 - Segments Offering Most New Opportunities
35.3 Parkinson's Disease Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer